XILIO THERAPEUTICS INC. - COMMON STOCK

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

08 1 2024 06:30:00 提供 Nasdaq GlobeNewswire

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

07 12 2023 06:30:00 提供 Nasdaq GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

09 11 2023 15:01:00 提供 Nasdaq GlobeNewswire

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

03 11 2023 11:00:00 提供 Nasdaq GlobeNewswire

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

31 10 2023 08:15:00 提供 Nasdaq GlobeNewswire

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

27 9 2023 16:02:48 提供 Nasdaq GlobeNewswire

Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer

05 9 2023 07:30:00 提供 Nasdaq GlobeNewswire

Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

05 9 2023 06:30:00 提供 Nasdaq GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results

14 8 2023 06:30:00 提供 Nasdaq GlobeNewswire

Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer

03 8 2023 15:05:01 提供 Nasdaq GlobeNewswire

Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors

25 5 2023 16:01:00 提供 Nasdaq GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results

09 5 2023 06:30:01 提供 Nasdaq GlobeNewswire

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 4 2023 15:05:00 提供 Nasdaq GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results

02 3 2023 15:05:01 提供 Nasdaq GlobeNewswire

Xilio Therapeutics to Present at Upcoming Investor Conferences

27 2 2023 06:30:00 提供 Nasdaq GlobeNewswire

Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit

16 2 2023 06:30:00 提供 Nasdaq GlobeNewswire

Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

02 2 2023 06:30:00 提供 Nasdaq GlobeNewswire

Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12

23 11 2022 06:30:00 提供 Nasdaq GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results

09 11 2022 06:30:00 提供 Nasdaq GlobeNewswire

Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’ Summit

04 11 2022 06:30:00 提供 Nasdaq GlobeNewswire